

520 Rec'd PCT/PTO 13 SEP 1999

09/381055

1103326-0590

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED OFFICE (DO/US)

<u>PCT/SE99/00702</u>	<u>28 APRIL 1999</u>	<u>28 APR. 1998 & 18 NOV. 1998</u>
International Application Number	International Filing Date	Priority Date(s) Claimed

NOVEL USE
Title of Invention

ASGHAR, Aziz; CABERO, Jose Luis; DRAY, Andrew; and KING, Anne

Applicant(s) for DO/US

"Express Mail" Label No EH623283195US

Date of Deposit SEPTEMBER 13, 1999

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Assistant Commissioner for Patents,
Washington, D.C. 20231

Robert Smith
(Type or print name of person mailing paper or fee)

Robert Smith
(Signature of person mailing paper or fee)

BOX PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

To the United States Designated Office (DO/US):

I. Accompanying this transmittal letter are certain items which are required under 35 U.S.C. 371 in order that United States National processing of the above identified International application may commence:

- (X) at the expiration of the applicable time limit under PCT Articles 22 and 39(1) according to the provisions of 35 U.S.C. 371(b).
- () as soon as possible upon receipt of this express request under 35 U.S.C. 371(f).

1. The U.S. National fee [35 U.S.C. 371(c)(1)]

a. () was previously transmitted by applicant on (date)_____.

b. (X) is submitted herewith as follows:

<u>FOR</u>	<u>NO. FILED</u>	<u>NO. EXTRA</u>	<u>SMALL ENTITY</u>			<u>OTHER THAN</u>	
			<u>RATE</u>	<u>FEE</u>	<u>or</u>	<u>RATE</u>	<u>FEE</u>
Basic Fee	(USPTO NOT ISA OR IPEA)		////	\$485	<u>or</u>	////	\$970
Total Claims	- 20 =	--	x 9 =		<u>or</u>	x18 =	
Ind. Claims	3 - 3		x39 =		<u>or</u>	x78 =	
() Multiple Dependent Claim Presented			+130 =		<u>or</u>	+260 =	
<u>TOTAL</u>							
<u>NATIONAL FEE</u>				\$ _____	<u>or</u>		\$970

i. () A check in the amount of \$_____ is enclosed.

ii. (X) Please charge the filing fee, multiple dependent claim fee (if applicable), excess independent claims fee (if applicable), and excess total claims fee (if applicable) to **Deposit Account No. 23-1703**.

iii. (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-1703. A duplicate copy of this sheet is enclosed.

(iv) () The filing fee is not enclosed.

2. A copy of the International application as filed [35 U.S.C. 371(c)(2)]:

a. (X) is transmitted herewith.

b. () is not required as the application was filed with the United States Receiving Office.

c. () has been transmitted

- i. ☐ by the International Bureau. Date of mailing of the application (from form PCT/IB/308): _____ A copy of form PCT/IB/308 is enclosed.
- ii. ☐ by applicant on (date) _____.
3. A translation of the International application into the English language [35 U.S.C. 371(c)(2)]:
- a. ☐ is transmitted herewith.
- b. ☒ is not required as the application was filed in English.
- c. ☐ was previously transmitted by applicant on (date) _____.
4. Amendments to the claims of the International application under PCT Article 19 [35 U.S.C. 371(c)(3)]:
- a. ☐ are transmitted herewith.
- b. ☐ have been transmitted
- i. ☐ by the International Bureau. Date of mailing of the amendments (from form PCT/IB/308): _____.
- ii. ☐ by applicant on (date) _____.
- c. ☒ have not been transmitted as
- i. ☐ no notification has been received that the International Searching Authority has received the Search Copy.
- ii. ☐ the Search Copy was received by the International Searching Authority but the Search Report has not yet issued. Date of receipt of Search Copy (from form PCT/ISA/202): _____.
- iii. ☐ applicant chose not to make amendments under PCT Article 19. Date of mailing of Search Report (from form PCT/ISA/210): _____.

iv. (X) the time limit for the submission of amendments has not yet expired. The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit under PCT Rule 46.1.

5. A Translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)]:

- a. () is transmitted herewith.
- b. () is not required as the amendments were made in the English language.
- c. (X) has not been transmitted for reasons indicated at point I.4.b. or c. above.

6. Three executed declarations for patent application of the inventor [35 U.S.C. 371(c)(4)] complying with 35 U.S.C. 115:

- a. () was previously submitted by applicant on (date)

- b. (X) are submitted herewith;
and such oaths or declarations
 - i. (X) are attached to the application.
 - ii. (X) identify the application and any amendments under PCT Article 19 which were transmitted as stated in points 1.2.b. or c. and 1.4. and states that they were reviewed by the inventor as required by 37 CFR 1.70.
- c. () will be submitted subsequently.

II. Concerning other documents:

- 1. An International Search Report or Declaration under PCT Article 17(2)(a):
 - a. () has been transmitted by the International Bureau. Date of mailing (from form PCT/IB/308): _____ A copy of form PCT/IB/308 is enclosed
 - b. () is not required as the application was searched by the United States International Searching Authority.

c. ☐ A copy of the International Search Report is transmitted herewith.

d. ☐ has been submitted by applicant on (date) _____.

2. A Statement of prior art under 37 CFR 1.97 and 1.98:

a. ☐ is transmitted herewith including copies of the references cited on the attached form PTO-1449. Also enclosed is a copy of the International-Type Search Report issued in the Swedish priority application.

b. ☐ will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).

c. ☐ was previously submitted by applicant on _____, in application serial no. _____.

3. ☐ An Assignment is transmitted herewith for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

a. ☐ Please charge the \$40.00 assignment recordation fee to Deposit Account No. 23-1703.


b. ☐ A check in the amount of \$___ is enclosed.

4. Other document(s) or information included:

- Copy of PCT/RO/101 - The PCT Request Form;
- five sheets of drawings; and.
- a return postcard.

September 13, 1999
DATE

Respectfully submitted,


Richard J. Sterner
Reg. No. 35,372

White & Case LLP
Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787
(212) 819-8200

enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Asghar, et al
Serial No. : 09/381,055 (U.S. National Stage
of International Application No. PCT/SE99/00702)
Examiner : To Be Assigned
Filed : September 13, 1999 Group Art Unit: To Be Assigned
For : NOVEL USE

I hereby certify that this paper is being
deposited with the United States Postal
Service as first class mail in an envelope
addressed to : The Assistant Commissioner
for Patents, Washington, D.C. 20231, on
October 27, 2000.

Richard V. Sterner
Agent Name
Richard V. Sterner
Signature

35,372
PTO Reg. No.
October 27, 2000
Date of Signature

19 DEC 2000

BOX PCT

The Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT


Sir:

Preliminary to examination on the merits, please amend the
application as follows:

In the claims:

1. (amended) Use a compound having NMDA receptor antagonist
activity in the manufacture of a medicament for the treatment of
irritable bowel syndrome (IBS).
2. (amended) Use according to claim 1 wherein the compound
having NMDA receptor antagonist activity is a non-competitive
NMDA receptor antagonist.

3. (amended) Use according to claim 1 wherein the compound having NMDA receptor antagonist activity is a compound of formula (I) :



where:

R¹ and R² are independently phenyl or 4-fluorophenyl;

R³ is hydrogen, C₁₋₆ alkyl or methoxycarbonyl;

R⁴ is hydrogen or methyl;

and metabolites and isomers thereof both as a free base and pharmaceutically acceptable salts thereof.

9. (amended) A method of treating or preventing irritable bowel syndrome which comprises administering to a patient in the need thereof a compound having NMDA receptor antagonist activity or a pharmaceutically acceptable salt thereof.

10. (amended) A pharmaceutical composition for the treatment of irritable bowel syndrome comprising a compound having NMDA receptor antagonist activity and a pharmaceutically acceptable carrier.

11. (amended) [Pharmaceutical] The pharmaceutical composition according to claim 10, wherein the compound having NMDA receptor

Efficiently designed, the **L**ibrary of Theological Studies is a series of books which will help you understand the Bible more fully. Each book is written by a leading expert in his field. The series includes:

$$\text{R}^1\text{-CH}_2\text{-}\overset{\overset{\text{R}^2}{|}}{\underset{\underset{\text{R}^3}{|}}{\text{C}}}\text{-}\overset{\overset{\text{O}}{\parallel}}{\text{N}(\text{R}^4)}\text{CH}_2\text{NH}_2 \quad (\text{I})$$

R¹ and R² are independently phenyl or 4-fluorophenyl;

R³ is hydrogen, C₁₋₆ alkyl or methoxycarbonyl;

R^4 is hydrogen or methyl;

and metabolites and isomers thereof both as a free base and pharmaceutically acceptable salts thereof.

Claims 1-12 are pending in the application. Claims 1-3 and 9-12 have been amended. The amendments reflect the amendments submitted by Applicants on July 21, 2000 during prosecution in the International Stage. Other amendments have been made in the

姓名	性别	年龄	籍贯	民族	文化程度	职业	婚姻	子女	备注
王德胜	男	45	山东	汉族	高中	教师	已婚	2	
李小明	男	38	河南	汉族	初中	工人	已婚	1	
张小红	女	32	江苏	汉族	大学	医生	已婚	0	
赵国强	男	50	河北	汉族	小学	农民	已婚	3	
孙丽娟	女	42	浙江	汉族	高中	护士	已婚	1	
周大伟	男	35	湖北	汉族	大学	工程师	已婚	0	
吴小芳	女	28	湖南	汉族	初中	售货员	已婚	1	
郑为民	男	48	四川	汉族	高中	干部	已婚	2	
陈秀英	女	55	广东	汉族	小学	退休	已婚	3	
黄志坚	男	30	广西	汉族	大学	程序员	未婚	0	
林小华	女	25	福建	汉族	高中	学生	未婚	0	
徐建国	男	40	江西	汉族	初中	工人	已婚	1	
马小丽	女	33	山西	汉族	大学	教师	已婚	0	
周国强	男	52	陕西	汉族	小学	农民	已婚	2	
吴小芳	女	47	甘肃	汉族	高中	护士	已婚	1	
郑为民	男	37	宁夏	汉族	大学	工程师	已婚	0	
陈秀英	女	29	青海	汉族	初中	售货员	已婚	1	
黄志坚	男	43	新疆	汉族	高中	干部	已婚	2	
林小华	女	31	内蒙古	汉族	大学	教师	已婚	0	
徐建国	男	27	吉林	汉族	初中	工人	已婚	1	
马小丽	女	39	辽宁	汉族	高中	售货员	已婚	0	
周国强	男	49	黑龙江	汉族	小学	农民	已婚	3	
吴小芳	女	51	吉林	汉族	初中	退休	已婚	2	
郑为民	男	34	辽宁	汉族	大学	程序员	未婚	0	
陈秀英	女	26	吉林	汉族	高中	学生	未婚	0	
黄志坚	男	41	辽宁	汉族	初中	工人	已婚	1	
林小华	女	36	吉林	汉族	大学	教师	已婚	0	
徐建国	男	28	辽宁	汉族	高中	售货员	已婚	1	
马小丽	女	44	吉林	汉族	小学	农民	已婚	2	
周国强	男	53	辽宁	汉族	初中	退休	已婚	3	
吴小芳	女	46	吉林	汉族	高中	护士	已婚	1	
郑为民	男	36	辽宁	汉族	大学	工程师	已婚	0	
陈秀英	女	30	吉林	汉族	初中	售货员	已婚	1	
黄志坚	男	44	辽宁	汉族	高中	干部	已婚	2	
林小华	女	32	吉林	汉族	大学	教师	已婚	0	
徐建国	男	29	辽宁	汉族	初中	工人	已婚	1	
马小丽	女	40	吉林	汉族	高中	售货员	已婚	0	
周国强	男	50	辽宁	汉族	小学	农民	已婚	3	
吴小芳	女	52	吉林	汉族	初中	退休	已婚	2	
郑为民	男	35	辽宁	汉族	大学	程序员	未婚	0	
陈秀英	女	27	吉林	汉族	高中	学生	未婚	0	
黄志坚	男	42	辽宁	汉族	初中	工人	已婚	1	
林小华	女	37	吉林	汉族	大学	教师	已婚	0	
徐建国	男	30	辽宁	汉族	高中	售货员	已婚	1	
马小丽	女	45	吉林	汉族	小学	农民	已婚	2	
周国强	男	54	辽宁	汉族	初中	退休	已婚	3	
吴小芳	女	47	吉林	汉族	高中	护士	已婚	1	
郑为民	男	37	辽宁	汉族	大学	工程师	已婚	0	
陈秀英	女	31	吉林	汉族	初中	售货员	已婚	1	
黄志坚	男	45	辽宁	汉族	高中	干部	已婚	2	
林小华	女	33	吉林	汉族	大学	教师	已婚	0	
徐建国	男	30	辽宁						

Dated: October 27, 2000

Richard Sterne

Agent's Direct line:
(212) 819-8783

5/PRTS

09/381055

420 Rec'd PCT/PTO 13 SEP 1999

1

NOVEL USE

Field of the invention

The present invention relates to the use of compounds having NMDA antagonist activity for treating certain conditions in the gastro intestinal tracts, such as functional gastrointestinal disorders, and in particular irritable bowel syndrome (IBS), where the condition known as visceral hypersensitivity may be a major contributory factor in the observed symptoms. The invention also relates to pharmaceutical compositions intended for the treatment of IBS.

Background of the invention

Compounds having NMDA (N-methyl-D-aspartate) antagonist activity are known in the art, for example see Watkins et al., Trends in Pharmacological Science, 11:25, 1990.

In particular certain compounds are disclosed in EP-A 279937 as having NMDA antagonist activity and are useful for treating various CNS disorders such as epilepsy and Parkinson's disease. In particular the compound known as remacemide is known from EP-A 279937 as an NMDA antagonist and has also been shown to act as a sodium channel antagonist (Wamil et al., Epilepsy Research 23:1. 1996). It has now surprisingly been found that antagonists of the NMDA receptor have an attenuating effect on the visceromotor response to colorectal distention in rats when dosed intravenously but not when dosed intrathecally.

This observation coupled with the observation that the compounds also show an attenuating effect in a model of pelvic nerve afferent activity, would suggest that the effect of these NMDA antagonists is dependant at least in part on a peripheral component. It does not however, rule out an additional action at the spinal or supra-spinal level, in the attenuation of the response to colorectal distension. As a result it is expected that compounds having NMDA antagonist activity which in some cases may be combined with sodium channel antagonist activity will be useful for the treatment of certain conditions in the gastro intestinal tracts where the phenomenon of visceral hypersensitivity may be involved, such as functional bowel disorders, and in particular irritable bowel syndrome.

Suitable NMDA antagonists include those listed in WO 94/13295 such as a) channel blockers, i.e. antagonists which operate in an uncompetitive or non-competitive manner to block the NMDA receptor channel, b) receptor antagonists that compete with NMDA to act at the NMDA binding site, c) agents acting at either the glycine co-agonist site or any of the several modulation sites such as the zinc site, the magnesium site, the redox

modulatory site, or the polyamine site, d) agents which inhibit the downstream effects of NMDA receptor stimulation such as agents which inhibit the activation of protein kinase C activation by NMDA stimulation, antioxidants, and agents that decrease phosphatidylinositol metabolism.

5


The hypersensitive state, such as that which may occur in patients with functional bowel disorders, may occur as a result of excessive receptor activation. Hence, antagonists which operate in an uncompetitive or non-competitive manner, may offer an advantage as they can only block the receptor when it is in its activated state and not when it is in its non-activated form. Thus excess receptor activity will be curtailed.

10

Examples of preferred compounds useful for the invention include but are not limited to memantine (Merz) and remacemide and their metabolites

15

Particularly suitable compounds are those disclosed in EPA 279937, such as a compound of formula (I):



20

where:

R¹ and R² are independently phenyl or 4-fluorophenyl;

R³ is hydrogen, C₁₋₆ alkyl or methoxycarbonyl;

R⁴ is hydrogen or methyl;


and metabolites and isomers thereof both as free base and pharmaceutically acceptable

25

salts thereof.

Preferred compounds of formula (I) include 2-amino-N-(1,2-diphenyl-1-methylethyl)acetamide (remacemide) or a metabolite thereof, such as the compound 2,3-diphenyl-2-propylamine or a pharmaceutically acceptable salt thereof which has the following structure:

30



Other preferred compounds include those disclosed in WO 93/20052, in particular (S)-1-phenyl-2-(2-pyridyl)ethanamine as well as the compounds mentioned in the experimental section herein. Certain compounds mentioned herein are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these individual stereoisomeric forms and to any mixtures thereof including racemates. The invention also extends to any tautomeric forms of the compounds mentioned and mixtures thereof.

Suitable salts of the above noted compounds include all known pharmaceutically acceptable salts such as acid addition salts and preferably hydrochloride salts.

Compounds which possess anti-inflammatory properties are useful in the prevention of clinical hyperalgesia and other pathologies associated with chronic pain such as neuropathies and joint inflammation. Particular inflammatory disorders which can be treated include arthritic conditions, eczema, psoriasis, dermatitis and other inflammatory conditions such as sunburn; inflammatory eye conditions such as uveitis and conjunctivitis; lung disorders in which inflammation is involved such as asthma and bronchitis; conditions of the GI tract including aphthous ulcers, gingivitis, Crohn's disease, atrophic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, peptic ulceration, IBS, pyresis, pain, including inflammatory induced pain, and other damage to the GI tract, for example damage from infections by, for example, *Helicobacter pylori*, or undesirable side effects from treatments with non-steroidal anti-inflammatory drugs.

Outline of the invention

In a preferred embodiment it has been found that certain NMDA antagonists are expected to be useful for the treatment of certain conditions in the GI tract, in particular functional bowel disorders.

In a further aspect the invention therefore provides use of an NMDA antagonist for the treatment or prevention of irritable bowel syndrome (IBS). Suitable NMDA antagonists

include those listed above. In particular a preferred aspect of the invention relates to the use of non-competitive NMDA antagonists such as memantine for the treatment of IBS. Other preferred compounds for the treatment or prevention of IBS include remacemide, and also compounds of formula I, such as (S)-1-phenyl-2-(2-pyridyl)ethanamine, 2-amino-
5 N-(1,2-diphenylethyl)acetamide hydrochloride, alpha-phenyl-1H-pyrazole-1-ethanamine hydrochloride, (+)-N-ethyl-1-phenyl-2-(3-pyrazine)ethanamine hydrochloride and 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine trihydrochloride.

10 In a preferred embodiment the invention provides a method of treating or preventing IBS which comprises administering to a patient in the need thereof a compound having NMDA antagonist activity or a pharmaceutically acceptable salt thereof.

15 The invention also provides the use of a compound having NMDA antagonist activity in the manufacture of a medicament for use in the prevention or treatment of IBS, and a pharmaceutical composition comprising such a compound and a pharmaceutical acceptable carrier.

20 Other diseases which may be treated with the compounds of the invention include functional gastrointestinal disorders as defined by the Rome group in *"The Functional Gastrointestinal Disorders"*, D. Drossman ed., Little Brown & Co., 1994, p.p. 370. In particular: irritable bowel syndrome and functional dyspepsia (non-ulcer dyspepsia) but also functional chest pain of presumed oesophageal origin, functional heartburn, functional dysphagia, non-cardiac chest pain, symptomatic gastro-oesophageal disease, gastritis, aerophagia, functional constipation, functional diarrhea, burbulence, chronic functional
25 abdominal pain, functional biliary pain, functional incontinence, functional ano-rectal pain, pelvic floor dyssnergia, un-specified functional ano-rectal disorder. Additional conditions include cholecystalgia, interstitial cystitis, dysmenorrhea, dyspareunia, cancer related pain, migraine, osteoarthritis and rheumatoid arthritis.

30 Use of the invention

Suitable daily dose ranges of the compound having NMDA antagonist activity are from about 1.0 mg/kg to about 100 mg/kg. Unit doses may be administered conventionally once or more than once a day, for example, 2, 3, or 4 times a day, more usually 1 or 2 times a day.

35

The following examples illustrate the invention.

Example 1**Effects of non-competitive NMDA glutamate receptor antagonists on the visceromotor response (VMR) elicited by colorectal distension (CRD)**

5

Methods:**Animals**

10 Adult male Sprague-Dawley rats (250-350g, Harlan, San Diego, CA) served as animal subjects. Rats were housed 5-6 per cage, allowed free access to food and water, and were maintained on a 12 h light-dark cycle (lights on between 06.00 and 18.00 h).

Surgical preparation

15 Rats were deeply anesthetized with pentobarbital sodium (45 mg/kg, Nembutal, Abbott Labs, North Chicago, IL) administered intraperitoneally. Electrodes (Teflon coated stainless steel wire, Cooner Wire Sales, Chatworth, CA) were stitched into the external oblique musculature, just superior to the inguinal ligament, for electromyographic (EMG) recording. The electrode leads were tunneled subcutaneously and exteriorized at the nape
20 of the neck for future access. Some animals were also implanted with venous catheters in the femoral vein to enable i.v. administration of drugs. For intrathecal (i.t.) drug administration, an i.t. catheter (PE-10 tubing, 8.5 cm long) was inserted through the dura overlying the atlanto-occipital junction and threaded to the level of the lumbar enlargement (Yaksh and Rudy, 1976). The venous or i.t. catheter was surgically anchored to
25 musculature at the back of the neck, and externalized with the electrode leads. The wounds were closed in layers with 4-0 silk. Rats were housed singly and allowed to recuperate for at least 3-5 days prior to testing.

Behavioral testing

30

The stimulus employed has been previously described (Gebhart and Sengupta, 1996). Briefly, the descending colon and rectum were distended by pressure-controlled air inflation of a 6 cm long flexible latex balloon tied around a flexible tube (Tygon). The balloon was lubricated (Surgilube, E. Fougera and Co., Melville, NY), inserted intra-anally

and anchored by taping the balloon catheter to the base of the tail. Noxious phasic CRD (80 mmHg, 20 s) was achieved with the aid of a device (developed in house at Astra Hässle.) Intracolonic pressure was continuously monitored on line. The behavioral response quantified was the visceromotor response, a contraction of the abdominal and hindlimb (Ness and Gebhart, 1988). EMG activity in the external oblique musculature was quantified by computing the average amplitude (Dr. Alfred Bayati Astra Hässle). Each distension trial lasted 60 s and EMG activity was quantified 20 s before distension (baseline), during distension, and 20 s after distension. The increase in EMG amplitude during distension over baseline was recorded as the response.

Experimental protocol

On the day of testing, animals were briefly anesthetized with Metophane®, and the balloon was inserted and secured in place as described above. Rats were allowed to recover for 30-40 min, following which two stable control responses to CRD (80 mmHg, 20 s, 4 min interstimulus interval) were obtained.

Drugs were administered i.v. into the femoral vein through the indwelling catheter. All doses were administered in a volume of up to 230 µl followed by a flush with 100 µl of preservative-free saline over a period of 30s. Dose response curves were generated using a cumulative dosing paradigm. The first i.v. injection was made 2 min after the second control response. Subsequent doses were injected 8 min apart, thus allowing two distensions after each dose. Data are reported as the average response to the two distensions.

In one group of animals, memantine was administered to the lumbar enlargement through the indwelling i.t. catheter with the aid of a 16 gauge injection needle connected to a 25 µl Hamilton syringe by a length of polyethylene tubing (PE-10). All doses were administered in a volume of 5 µl followed by a flush with 10 µl of preservative-free saline over a period of 1 min. The progress of the injection was continuously monitored by following the movement of an air bubble in the tubing. The dose response curve was generated using a cumulative dosing paradigm. The first i.t. injection was made 2 min after the second control response. Subsequent doses were injected 8 min apart, thus allowing two distensions after each dose. Data are reported as the average response to the two distensions.

Drugs

Drugs used in the present study were memantine hydrochloride (Research Biochemicals International, Natick, MA), and 2-amino-N-(1,2-diphenylethyl)acetamide hydrochloride, alpha-phenyl-1H-pyrazole-1-ethanamine hydrochloride, (+)-N-ethyl-1-phenyl-2-(3-pyrazine)ethanamine hydrochloride and 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine trihydrochloride (Astra Arcus, Rochester, NY). Stock solutions were freshly prepared by dissolving the drugs in distilled water, and then diluted as needed.

Results:

All drugs administered i.v. produced a dose-dependent attenuation of the VMR to noxious CRD (80 mmHg) in naïve animals without producing any apparent motor effects. At the most effective dose tested, memantine (10 mg/kg) attenuated the VMR to 28 % of control, 2-amino-N-(1,2-diphenylethyl)acetamide hydrochloride (60 mg/kg) to 40 % of control, alpha-phenyl-1H-pyrazole-1-ethanamine hydrochloride (100 mg/kg) to 10 % of control, (+)-N-ethyl-1-phenyl-2-(3-pyrazine)ethanamine hydrochloride (60 mg/kg) to 5 % of control and 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine trihydrochloride to 13 % of control.

In contrast, memantine administered i.t. (1-100 nmol) was without effect in diminishing the VMR to CRD. This is supported by other studies wherein NMDA receptor antagonists administered i.t. were without effect on normal visceral nociceptive reflexes, except in doses that produce motor impairment (Rice and McMahon, 1994; Coutinho et al., 1996a; Ide et al., 1997).

These data suggest that memantine as well as the other open channel blockers tested may be interacting with peripheral NMDA receptors.

Therefore it appears that activity at peripheral NMDA receptors plays a role in modulating responses to CRD.

Results are presented in Figures 1 to 4, which figures show the following:

Fig 1. Illustrates the effect of intravenous (i.v.) administration of memantine hydrochloride on visceromotor responses (VMR) to noxious colorectal distension of conscious rats. Memantine dose-dependently attenuate VMR when given i.v. from 1-10 mg/kg.

- 5 Fig 2. Effect of intrathecal (i.t.) administration of memantine hydrochloride on visceromotor responses (VMR) to noxious colorectal distension of conscious rats. Memantine did not attenuate VMR when given i.t. up to a dose of 100 nmol.

- 10 Fig 3. Effect of intravenous (i.v.) administration of four compounds on visceromotor responses (VMR) to noxious colorectal distension of conscious rats. All four compounds dose-dependently (1-10 mg/kg) attenuated VMR.

Compound 1 is 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine trihydrochloride

Compound 2 is 2-amino-N-(1,2-diphenylethyl)acetamide hydrochloride

Compound 3 is (+) N-ethyl-1-phenyl-2-(3-pyrazine)ethanamine hydrochloride

- 15 Compound 4 is alpha-phenyl-1H-pyrazole-1-ethanamine hydrochloride

Fig 4. Effect of intrathecal (i.t.) administration of three compounds on visceromotor responses (VMR) to noxious colorectal distension of conscious rats. None of the three compounds attenuated VMR up to a dose of 300nmol.

- 20 Compound 1 is 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine trihydrochloride

Compound 2 is 2-amino-N-(1,2-diphenylethyl)acetamide hydrochloride

Compound 4 is alpha-phenyl-1H-pyrazole-1-ethanamine hydrochloride

25

Example 2

Effects of non-competitive NMDA glutamate receptor antagonists on pelvic afferent nerve activity

- 30 General procedures: Male Sprague-Dawley rats (425-450 g) were anesthetized initially with sodium pentobarbital (40-45 mg/kg ip) and maintained with α -chloralose (60 mg kg⁻¹ h⁻¹). The trachea was cannulated for mechanical ventilation with room air. The left common carotid artery was cannulated for recording blood pressure. The femoral artery and vein were catheterized for injection of drug and anesthetic, respectively. Rats were
- 35 paralyzed with pancuronium bromide (0.3 mg/kg i.v.) and ventilated with room air (55-60 strokes/min and 3-4 ml stroke volume). Supplemental doses of pancuronium bromide (0.2-

0.3 mg kg⁻¹ h⁻¹) were given to maintain paralysis during the course of experiment. The mean arterial blood pressure was monitored continuously and maintained at >80 mm Hg with supplemental intravenous injection of 5% dextrose in saline given in a bolus of 1 to 1.5 ml as required. The core body temperature was maintained at 36°C by a hot-water-circulating heating pad underneath the rat and a feedback-controlled heat lamp (thermoprobe inserted into the thoracic esophagus). At the end of an experiment, the rat was killed by an overdose of intravenous pentobarbital sodium.

Surgical procedure: The lower abdomen was exposed by a 3-4 cm long incision laterally at the left flank. The urinary bladder was emptied and catheterized (PE-100) through the fundus. The urethra was ligated close to its entry to the penis and urine was constantly evacuated via the fundic catheter.

The pelvic nerve was approached near the major pelvic ganglion and isolated. A pair of Teflon-coated stainless steel wires stripped at the tips were wrapped around the pelvic nerve and sealed with non-reactive Wacker gel. The hypogastric, pudendal, and femoral nerves were isolated and transected. The sciatic nerve was approached through the ischiatic notch and transected. The abdomen was closed with silk sutures.

The lumbosacral spinal cord was exposed by laminectomy (T₁₃-S₂) and the rat was suspended from thoracic vertebral and ischial spinal clamps. The dorsal skin was reflected laterally and tied to make a pool for mineral oil. The dura was carefully removed and the spinal cord was covered with warm (37°C) mineral oil. For colorectal distension (CRD), a 6 - 7-cm long, 2 - 3 cm diameter flaccid, flexible latex balloon was inserted into the descending colon and rectum as described above.

Recordings of afferent nerve action potentials: The S₁ dorsal root was identified and decentralized at its entry to the spinal cord. Recordings were made from the distal cut end of the central processes of primary afferent fibers. a length of nerve fiber was draped over a black micro-base plate immersed in warm (37°C) mineral oil. The dorsal rootlet was split into thin bundles and a fine filament was isolated from the bundle to obtain a single unit. Electrical activity of single units was recorded monopolarly by placing a teased fiber over one arm of a bipolar silver-silver chloride electrode; a fine strand of connective tissue was placed across the other pole of the electrode. Action potentials were monitored continuously by analog delay and displayed on a storage oscilloscope after initial amplification through a low-noise ac differential amplifier. Action potentials were processed through a window discriminator and the frequency of impulses were counted (1s binwidth) on-line using the spike2/ced 1401 data acquisition program. Peri-stimulus time

histograms (PSTH), urinary bladder or colonic distending pressures, and blood pressure were displayed on-line.

Experimental protocol: Pelvic nerve input to the s_1 dorsal root was identified first by electrical stimulation of the pelvic nerve (a single 0.5 ms square-wave pulse at 5-8 mA).

- 5 The organ innervated was identified by response to phasic CRD (80mm Hg, 2-3s). If a fiber responded to CRD, a stimulus-response function to phasic distending pressures of 5, 10, 20, 30, 40, 60, 80, and 100 mm Hg, 30s each at 4 min intervals was determined.

- 10 The effect of the NMDA-antagonist, memantine, was tested on responses of mechanosensitive pelvic nerve afferents to 80 mm Hg of CRD. The drug was administered intra-arterially in a cumulative dose paradigm. Each dose of the drug was given 2 min before CRD. A cumulative dose-response relationship for memantine was obtained by giving 1, 3, 6 and 10 mg/kg.

- 15 Figure 5 shows the results for memantine and Figure 6 shows the corresponding results with 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine.

- 20 Results and conclusion: Intra-arterially injected memantine reduced, in a dose-dependent fashion, the pelvic nerve activity elicited by distention of the colon (80 mm Hg), as can be seen from Figure 5.

- 25 The observations hereby provided are consistant with a model in which the non-competitive NMDA-antagonist memantine reduces the pelvic nerve activity elicited by colorectal distention by a peripheral mechanism of action.

- The data shown in Figure 6 was obtained when the experiment was repeated with 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine.

References:

- 30 Coutinho S.V., Meller S.T. and Gebhart, G.F. (1996a) Intracolonic zymosan produces visceral hyperalgesia in the rat that is mediated by spinal NMDA and non-NMDA receptors. *Brain Res.* 736, 7-15.


- Coutinho, S.V., Urban, M.O. and Gebhart, G.F.(1996b) NMDA and non-NMDA receptors in the RVM modulate responses to colorectal distension from the inflamed colon. In: Abst. 8th World Cong. on Pain, pg.251, IASP Press, Seattle, WA.
- 5 Gebhart, G.F. and Sengupta, J.N. (1996) Evaluation of visceral pain. In *Handbook of Methods in Gastrointestinal Pharmacology* (ed. Gaginella, T.S.), pp. 359-374, CRC Press, Boca Raton.
- 10 Ide, Y., Maehara, Y., Tsukahara, S., Kitahata, L.M. and Collins, J.G. (1997) The effects of an intrathecal NMDA receptor antagonist (AP5) on the behavioral changes induced by colorectal inflammation with turpentine in rats. *Life Sci.* **60**, 1359-1363.
- 15 Ness T.J. and Gebhart, G.F. (1988) Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudoaffective reflexes in the rat. *Brain Res.* **450**, 153-169.
- 20 Rice, A.S.C. and McMahon, S.B. (1994) Pre-emptive intrathecal administration of an NMDA receptor antagonist (AP5) prevents hyper-reflexia in a model of persistent visceral pain. *Pain* **57**, 335-340.
- Yaksh, T.L. and Rudy, T.A. (1976) Chronic catheterization of the spinal subarachnoid space. *Physiol. Behav.* **17**, 1031-1036.

CLAIMS

1. Use a compound having NMDA antagonist activity in the manufacture of a medicament for the treatment of irritable bowel syndrome (IBS).

2. Use according to claim 1 wherein the compound having NMDA antagonist activity is a non-competitive NMDA antagonist.

3. Use according to claim 1 wherein the compound having NMDA antagonist activity is a compound of formula (I):



where:

R¹ and R² are independently phenyl or 4-fluorophenyl;

R³ is hydrogen, C₁₋₆ alkyl or methoxycarbonyl;

R⁴ is hydrogen or methyl;

and metabolites and isomers thereof both as a free base and pharmaceutically acceptable salts thereof.

4. Use according to claim 3 wherein the compound of formula (I) is remacemide or a pharmaceutically acceptable salt thereof.

5. Use according to claim 3 wherein the compound is 2,3-diphenyl-2-propylamine or a pharmaceutically acceptable salt thereof.

6. Use according to claim 3 wherein the compound is (S)-1-phenyl-2-(2-pyridyl)ethanamine or a pharmaceutically acceptable salt thereof.

7. Use according to claim 1 wherein the NMDA antagonist is memantine or a pharmaceutically acceptable salt thereof.

8. Use according to claim 1 where the compound is 2-amino-N-(1,2-diphenylethyl)acetamide, alpha-phenyl-1H-pyrazole-1-ethanamine, (+)-N-ethyl-1-phenyl-


2-(3-pyrazine)ethanamine, or 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine or a pharmaceutically acceptable salt thereof.

9. A method of treating or preventing irritable bowel syndrome which comprises
5 administering to a patient in the need thereof a compound having NMDA antagonist activity or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition for the treatment of irritable bowel syndrome comprising a compound having NMDA antagonist activity and a pharmaceutical
10 acceptable carrier.
11. Pharmaceutical composition according to claim 10, wherein the compound having NMDA antagonist activity is a non-competitive NMDA antagonist.
12. Pharmaceutical composition according to claim 10, wherein the compound having
15 NMDA antagonist activity is a compound of formula I defined in claim 3.

09381055.103000

1 / 5

Fig. 1



2/5

Fig. 2









Fig. 3







Fig. 4



5 / 5

Fig. 5



 $CV = 2 \text{ m/s}$
memantine dose-response

Fig. 6

 $CV = 2.3 \text{ m/s}$
Compound 1 dose-response

As a below named inventor, I hereby declare that:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled NOVEL USE the specification of which is attached hereto unless the following box is checked:

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Priority Not Claimed

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number) (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application Number)

(Filing Date)

(Status -- patented, pending, abandoned)

(Application Number)

(Filing Date)

(Status -- patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Edward V. Filardi, Reg. No. 25,757; Nels T. Lippert, Reg. No. 25,888; Dimitrios Drivas, Reg. No. 32,218; Robert B. Smith, Reg. No. 28,538; Cecilia O'Brien Lofters, Reg. No. 33,434; David Bender, Reg. No. 35,445; John M. Genova, Reg. No. 32,224; Richard J. Sterner, Reg. No. 35,372; Hans-Peter G. Hoffmann, Reg. No. 37,352; Thelma C. Cleland, Reg. No. 40,948; Leslie Morioka, Reg. No. 40,304; John Scheibeler, Reg. No. 35,346; and Roy Waldron III, Reg. No. 42,208, all of the firm of WHITE & CASE Limited Liability Partnership, with offices at 1155 Avenue of the Americas, New York, New York 10036.

Address all telephone calls to _____ at telephone number (212) 819-8200

Address all correspondence to WHITE & CASE LLP
Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor
(given name, family name)

Aziz Asghar

First inventor's signature

A. Asghar

Date:

21/07/99

Residence Address

West Yorkshire, United Kingdom

Citizenship

British

Post Office Address

School of Biomedical Sciences, The Worsley Building, University of Leeds, Leeds LS2 9NQ, United Kingdom

Full name of second joint inventor, if any
(given name, family name)

José Luis Cabero

Second inventor's signature

Date

Residence Address

Mölnådal, Sweden

Citizenship

Swedish

Post Office Address

Astra Hässle AB, S-431 83 Mölnådal, Sweden

Full name of third joint inventor, if any
(given name, family name)

Andrew Dray

Third inventor's signature

Date

Residence Address

Montreal, Canada

Citizenship

British

Post Office Address

Astra Research Centre Montreal, 7171 Frederick-Banting, St: Laurent, Quebec
H4S 1Z9, Canada

Full name of fourth joint inventor, if any
(given name, family name)

Anne King

Third inventor's signature

Date

19/07/99

Residence Address

Leeds, United Kingdom

Citizenship

British

Post Office Address

School of Biomedical Sciences, The Worsley Building, University of Leeds, Leeds LS2
9NQ, United Kingdom

As a below named inventor, I hereby declare that:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled NOVEL USE the specification of which is attached hereto unless the following box is checked:

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Priority Not Claimed

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

-1-

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application Number)

(Filing Date)

(Status -- patented, pending, abandoned)

(Application Number)

(Filing Date)

(Status -- patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Edward V. Filardi, Reg. No. 25,757; Nels T. Lippert, Reg. No. 25,888; Dimitrios Drivas, Reg. No. 32,218; Robert B. Smith, Reg. No. 28,538; Cecilia O'Brien Lofters, Reg. No. 33,434; David Bender, Reg. No. 35,445; John M. Genova, Reg. No. 32,224; Richard J. Sterner, Reg. No. 35,372; Hans-Peter G. Hoffmann, Reg. No. 37,352; Thelma C. Cleland, Reg. No. 40,948; Leslie Morioka, Reg. No. 40,304; John Scheibeler, Reg. No. 35,346; and Roy Waldron III, Reg. No. 42,208, all of the firm of WHITE & CASE Limited Liability Partnership, with offices at 1155 Avenue of the Americas, New York, New York 10036.

Address all telephone calls to _____ at telephone number (212) 819-8200

Address all correspondence to WHITE & CASE LLP
Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor
(given name, family name)

Aziz Asghar

First inventor's signature

Date:

Residence Address

West Yorkshire, United Kingdom

Citizenship British

Post Office Address

School of Biomedical Sciences, The Worsley Building, University of Leeds, Leeds LS2 9NQ, United Kingdom

Full name of second joint inventor, if any
(given name, family name)

José Luis Cabero

Second inventor's signature

Date

Residence Address

Möln dal, Sweden

Citizenship

Swedish

Post Office Address

Astra Hässle AB, S-431 83 Möln dal, Sweden

300
Full name of third joint inventor, if any
(given name, family name)

Andrew Dray

Third inventor's signature

Date

23rd July 1999

Residence Address

Montreal, Canada

Citizenship

British

Post Office Address

Astra Research Centre Montreal, 7171 Frederick-Banting, St: Laurent, Quebec
H4S 1Z9, Canada

Full name of fourth joint inventor, if any
(given name, family name)

Anne King

Third inventor's signature

Date

Residence Address

Leeds, United Kingdom

Citizenship

British

Post Office Address

School of Biomedical Sciences, The Worsley Building, University of Leeds, Leeds LS2
9NQ, United Kingdom

09384055-103000

As a below named inventor, I hereby declare that:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled NOVEL USE the specification of which is attached hereto unless the following box is checked:

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Priority Not Claimed

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

-1-

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

_____ (Application Number)	_____ (Filing Date)	_____ (Status -- patented, pending, abandoned)
_____ (Application Number)	_____ (Filing Date)	_____ (Status -- patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Edward V. Filardi, Reg. No. 25,757; Nels T. Lippert, Reg. No. 25,888; Dimitrios Drivas, Reg. No. 32,218; Robert B. Smith, Reg. No. 28,538; Cecilia O'Brien Lofters, Reg. No. 33,434; David Bender, Reg. No. 35,445; John M. Genova, Reg. No. 32,224; Richard J. Sterner, Reg. No. 35,372; Hans-Peter G. Hoffmann, Reg. No. 37,352; Thelma C. Cleland, Reg. No. 40,948; Leslie Morioka, Reg. No. 40,304; John Scheibeler, Reg. No. 35,346; and Roy Waldron III, Reg. No. 42,208, all of the firm of WHITE & CASE Limited Liability Partnership, with offices at 1155 Avenue of the Americas, New York, New York 10036.

Address all telephone calls to _____ at telephone number (212) 819-8200

Address all correspondence to WHITE & CASE LLP
Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor
(given name, family name)

Aziz Asghar

First inventor's signature

Date: _____

Residence Address

West Yorkshire, United Kingdom

Citizenship

British


Post Office Address

School of Biomedical Sciences, The Worsley Building, University of Leeds, Leeds LS2 9NQ, United Kingdom

200
Full name of second joint inventor, if any
(given name, family name)

José Luis Cabero

Second inventor's signature



Date

20 July 1999

Residence Address

Möndal, Sweden

SEX

Citizenship

Swedish

Post Office Address

Astra Hässle AB, S-431 83 Möndal, Sweden

Full name of third joint inventor, if any
(given name, family name)

Andrew Dray

Third inventor's signature

Date

Residence Address

Montreal, Canada

Citizenship

British

Post Office Address

Astra Research Centre Montreal, 7171 Frederick-Banting, St: Laurent, Quebec
H4S 1Z9, Canada

Full name of fourth joint inventor, if any
(given name, family name)

Anne King

Third inventor's signature

Date

Residence Address

Leeds, United Kingdom

Citizenship

British

Post Office Address

School of Biomedical Sciences, The Worsley Building, University of Leeds, Leeds LS2
9NQ, United Kingdom